Form 4: Director Robin Steele Receives Stock Option Grant

Dare Bioscience director Robin Steele was granted 10,000 stock options as part of standard equity compensation.

Summary

• Director Robin Steele was granted 10,000 stock options for common stock in Dare Bioscience, Inc.
• The options have an exercise price of $2.03 per share.
• The grant date is June 11, 2026, with an expiration date of June 11, 2036.
• The options vest in full on the earlier of the first anniversary of the grant date or the date of the first annual meeting of stockholders following the grant.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on the company's financial position.

Positives

• Equity-based compensation aligns the interests of the director with those of the shareholders.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• The value of the options is dependent on the future performance of the company's common stock price relative to the $2.03 exercise price.

Future Outlook

The options vest in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are a standard corporate governance practice in the biotechnology sector to incentivize long-term oversight and strategic alignment.

Comparison to Industry Standards

• The grant of 10,000 options is consistent with typical director compensation packages for small-cap biotechnology firms.
• Vesting schedules tied to annual meetings are standard practice for board members in the life sciences industry.

Corporate Governance

Stakeholder Impact

• Minor dilution impact for existing shareholders upon future exercise of options.

Next Steps

• Vesting of options on the earlier of June 11, 2027, or the next annual meeting of stockholders.

Key Dates

Keywords

Dare Bioscience, DARE, Form 4, Insider Trading, Stock Options, Director Compensation